Innovita Biological Technology Co Ltd
SSE:688253
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Innovita Biological Technology Co Ltd
Free Cash Flow
Innovita Biological Technology Co Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Innovita Biological Technology Co Ltd
SSE:688253
|
Free Cash Flow
¥269.3m
|
CAGR 3-Years
85%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shanghai Conant Optical Co Ltd
HKEX:2276
|
Free Cash Flow
¥261.8m
|
CAGR 3-Years
59%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Free Cash Flow
¥731.2m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Free Cash Flow
¥364.9m
|
CAGR 3-Years
42%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Free Cash Flow
¥917.2m
|
CAGR 3-Years
29%
|
CAGR 5-Years
13%
|
CAGR 10-Years
23%
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Free Cash Flow
-¥1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovita Biological Technology Co Ltd
Glance View
Innovita Biological Technology Co., Ltd. engages in the research and development, production, and sale of point-of-care testing rapid diagnostic products. The company is headquartered in Beijing, Beijing and currently employs 439 full-time employees. The company went IPO on 2022-07-28. The firm's main products include novel coronavirus (2019-nCoV) neutralizing antibody detection kits using colloidal gold, quantum dot fluorescence immunochromatography and chemiluminescence techniques, and respiratory pathogen detection products, such as whole blood respiratory quintuple detection card, influenza virus triple detection card, virus serum quintuple detection card, respiratory pathogen nine indirect immunofluorescence kit, and others.
See Also
What is Innovita Biological Technology Co Ltd's Free Cash Flow?
Free Cash Flow
269.3m
CNY
Based on the financial report for Dec 31, 2024, Innovita Biological Technology Co Ltd's Free Cash Flow amounts to 269.3m CNY.
What is Innovita Biological Technology Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
61%
Over the last year, the Free Cash Flow growth was 11%. The average annual Free Cash Flow growth rates for Innovita Biological Technology Co Ltd have been 85% over the past three years , 61% over the past five years .
